The IT Law Wiki
Line 4: Line 4:
   
 
The following issues were identified: responding to unsolicited requests; fulfilling regulatory requirements when using [[social media tools|tools]] associated with space limitations; fulfilling post-marketing submission requirements; [[online]] [[communication]]s for which manufacturers, packers, or distributors are accountable; use of [[link]]s on the [[Internet]]; and correcting [[misinformation]].
 
The following issues were identified: responding to unsolicited requests; fulfilling regulatory requirements when using [[social media tools|tools]] associated with space limitations; fulfilling post-marketing submission requirements; [[online]] [[communication]]s for which manufacturers, packers, or distributors are accountable; use of [[link]]s on the [[Internet]]; and correcting [[misinformation]].
  +
  +
Following the hearing, the [[FDA]] and solicited written comments through a public docket that was open from September 2009 to February 2010.
   
 
Following this meeting the [[FDA]] did not issue any guidelines, but stated that it would "look at [Internet] issues on a case-by-case basis," while reserving the right to revaluate the need for regulations in the future.<ref>''See'' The Pink Sheet (Nov. 8, 1999), at 22 (Statement of Melissa Moncavage, DDMAC Public Health Advisor, at Drug Information Association conference on Oct. 23, 1999).</ref>
 
Following this meeting the [[FDA]] did not issue any guidelines, but stated that it would "look at [Internet] issues on a case-by-case basis," while reserving the right to revaluate the need for regulations in the future.<ref>''See'' The Pink Sheet (Nov. 8, 1999), at 22 (Statement of Melissa Moncavage, DDMAC Public Health Advisor, at Drug Information Association conference on Oct. 23, 1999).</ref>

Revision as of 03:32, 24 May 2012

Overview

On November 12 and 13, 2009, the Food and Drug Administration (FDA) held a public meeting titled Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools to discuss issues related to the promotion of FDA-regulated medical products on the Internet and social media tools.

The following issues were identified: responding to unsolicited requests; fulfilling regulatory requirements when using tools associated with space limitations; fulfilling post-marketing submission requirements; online communications for which manufacturers, packers, or distributors are accountable; use of links on the Internet; and correcting misinformation.

Following the hearing, the FDA and solicited written comments through a public docket that was open from September 2009 to February 2010.

Following this meeting the FDA did not issue any guidelines, but stated that it would "look at [Internet] issues on a case-by-case basis," while reserving the right to revaluate the need for regulations in the future.[1]

References

  1. See The Pink Sheet (Nov. 8, 1999), at 22 (Statement of Melissa Moncavage, DDMAC Public Health Advisor, at Drug Information Association conference on Oct. 23, 1999).

See also

External links